Janux Therapeutics, Inc. (JANX)
18.00
-0.78
(-4.15%)
USD |
NASDAQ |
Aug 28, 16:00
18.00
0.00 (0.00%)
After-Hours: 16:40
Janux Therapeutics Shareholders Equity (Quarterly) : 927.98M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 927.98M |
| March 31, 2026 | 941.54M |
| December 31, 2025 | 956.82M |
| September 30, 2025 | 976.56M |
| June 30, 2025 | 990.52M |
| March 31, 2025 | 1.012B |
| December 31, 2024 | 1.023B |
| September 30, 2024 | 656.10M |
| June 30, 2024 | 657.68M |
| March 31, 2024 | 655.76M |
| December 31, 2023 | 344.35M |
| September 30, 2023 | 348.95M |
| Date | Value |
|---|---|
| June 30, 2023 | 299.47M |
| March 31, 2023 | 311.26M |
| December 31, 2022 | 320.74M |
| September 30, 2022 | 331.51M |
| June 30, 2022 | 343.81M |
| March 31, 2022 | 356.08M |
| December 31, 2021 | 366.33M |
| September 30, 2021 | 376.75M |
| June 30, 2021 | 384.80M |
| March 31, 2021 | 60.58M |
| December 31, 2020 | 6.986M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| MacroGenics, Inc. | 42.87M |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.008B |
| Total Liabilities (Quarterly) | 79.67M |
| Debt to Equity Ratio | 0.0226 |
| Current Ratio | 16.35 |
| Net Debt Paydown Yield | 0.03% |